Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Equivalents (2022 - 2025)

Gossamer Bio's Cash & Equivalents history spans 4 years, with the latest figure at $22.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 51.82% year-over-year to $22.2 million; the TTM value through Dec 2025 reached $22.2 million, down 51.82%, while the annual FY2025 figure was $22.2 million, 51.82% down from the prior year.
  • Cash & Equivalents reached $22.2 million in Q4 2025 per GOSS's latest filing, up from $8.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $153.5 million in Q3 2022 to a low of $3.8 million in Q2 2023.
  • Average Cash & Equivalents over 4 years is $50.2 million, with a median of $30.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: tumbled 96.98% in 2023, then surged 2186.24% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $112.0 million in 2022, then tumbled by 71.32% to $32.1 million in 2023, then soared by 43.49% to $46.1 million in 2024, then crashed by 51.82% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Cash & Equivalents are $22.2 million (Q4 2025), $8.9 million (Q3 2025), and $26.3 million (Q2 2025).